the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis

Launched by TANTA UNIVERSITY · Nov 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of diosmin, a natural substance, in treating patients with mild to moderately active ulcerative colitis. Participants will take diosmin tablets daily for three months to see if it helps improve their condition compared to those not taking the tablets. The study will track changes in disease activity to determine how effective and safe diosmin is for managing ulcerative colitis.

To be eligible for this trial, participants must be at least 18 years old and newly diagnosed with mild or moderate ulcerative colitis. They should be currently receiving treatment with a medication called mesalamine. However, this study is not open to individuals with severe ulcerative colitis, certain other health conditions, or those on specific medications that could interfere with the trial. If you choose to participate, you can expect regular check-ins and assessments over the three-month period to monitor your progress and any side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old.
• • Both male and female sex.
• • Newly diagnosed patients with mild and moderate ulcerative colitis and treated with 5-aminosalicylic acid (mesalamine).
• Exclusion Criteria:
• • Patients with severe ulcerative colitis.
• • Patients with colorectal cancer.
• • Patients on rectal or systemic steroids.
• • Patients on immunosuppressants or biological therapies.
• • Patients with previously failed treatment with sulphasalazine.
• • Patients with known allergy to study medications.
• • History of complete or partial colectomy.
• • Patients with heart diseases and arrhythmia.
• • Patients on blood thinning agents.
• • Patients on anticoagulants (warfarin), anticonvulsants (carbamazepine and phenytoin), muscle relaxants (chlorzoxazone) and non-steroidal anti-inflammatory drugs (diclofenac).